Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- Ionis Pharmaceuticals lowered TRYNGOLZA 2026 product sales guidance to ~$50 million from $100-110 million after a more gradual launch ramp, while reaffirming 2026 total revenue guidance of $875-900 million.
- 10-Q report · filed Nov 9, 2026
- Ionis Pharmaceuticals reported nine-month 2026 revenue of $756.8 million, up from $740.4 million, while net loss widened to $317.1 million from $152.0 million. Eplontersen and pelacarsen Phase 3 trials missed primary endpoints; ulefnersen and sefaxersen reported positive Phase 3 results.
The audio replay and transcript follow the call.